Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards on March 26, 2026 to two new employees under its 2015 New Employee Incentive Plan.

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards on March 26, 2026 to two new employees under its 2015 New Employee Incentive Plan.

The awards total 300,000 stock options (10-year term, $0.243 exercise price) and 300,000 RSUs. Options vest over four years; RSUs vest over three years.

Argus Apr 1 session

-4.18% close to close Open Argus

Details

News Market Reaction – PSTV

On Apr 1, the first trading day after this news, PSTV closed 4.18% below the previous close.

Data tracked by StockTitan Argus for the Apr 1 session.

Key Figures

Stock options granted: 300,000 options RSUs granted: 300,000 RSUs Option term: 10 years +3 more

Stock options granted

300,000 options

Inducement awards to two new employees on Mar 26, 2026

RSUs granted

300,000 RSUs

Inducement awards under 2015 New Employee Incentive Plan

Option term

10 years

Term of employee inducement stock options

Option exercise price

$0.243

Exercise price equal to fair market value on Mar 26, 2026

Option vesting period

4 years

25% after 1 year, then 1/36th monthly thereafter

RSU vesting period

3 years

1/3 after 1 year, remainder over next 8 quarters

Historical Context

5 past events · Latest: Mar 26

5 events

1. Mar 26

   Board appointment

   24h Move

   -1.2%

   Veteran diagnostics executive Ron Andrews added to Board for CNSide scaling.

2. Mar 19

   Health economics data

   24h Move

   +2.2%

   ISPOR analysis suggesting CNSide may cut LM healthcare costs by ~40%.

3. Mar 12

   Earnings and outlook

   24h Move

   -15.2%

   2025 results with cash of $13.1M and 2026 milestones for REYOBIQ and CNSide.

4. Feb 25

   New CPT code

   24h Move

   +7.6%

   Category III CPT code X566T approved for REYOBIQ convection-enhanced delivery.

5. Jan 22

   Business update

   24h Move

   -2.3%

   Business update plus upsized $15M offering to fund REYOBIQ and CNSide goals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, exercise price, fair market value, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement awards under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"300,000 restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options have a 10-year term and an exercise price equal to $0.243"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fair market value financial

"exercise price equal to $0.243, the fair market value of the Company’s common stock"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

vesting financial

"The options vest over a four-year period, with 25% of the shares subject to the options vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company.

The awards were granted on March 26, 2026 under the Company’s 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist in the aggregate of options to purchase 300,000 shares of Company common stock and 300,000 restricted stock units (“RSUs”).

The options have a 10-year term and an exercise price equal to $0.243, the fair market value of the Company’s common stock on the date of grant. The options vest over a four-year period, with 25% of the shares subject to the options vesting on the first anniversary of the vesting commencement date of March 26, 2026, and 1/36^th vesting on each monthly anniversary thereafter, subject to the employee’s continued service with the Company through each applicable vesting date.

Each RSU represents a contingent right to receive one share of the Company’s common stock and there is no exercise price associated with the RSUs granted thereunder. The RSUs vest over a three-year period, with 1/3 vesting on the first anniversary of the grant date, and the remaining RSUs vesting ratably over the next 8 quarters, subject to the employee’s continued service with the Company through each applicable vesting date.

The awards were approved by the Compensation Committee of the Company’s board of directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Rule 5635(c)(4).

About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as the CNSide® Tumor Cell Enumeration assay, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases.

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Plus Therapeutics (PSTV) grant on March 26, 2026?

The company granted a total of 300,000 options and 300,000 RSUs to two new hires. According to the company, options carry a 10-year term and an exercise price of $0.243, the fair market value on the grant date.

How do the PSTV options vest and what is the exercise price for the March 26, 2026 grant?

Options vest over four years with 25% after one year, then monthly thereafter. According to the company, the options have a $0.243 exercise price and a 10-year term from grant.

What are the vesting terms for the PSTV restricted stock units granted March 26, 2026?

RSUs vest over three years with one-third at the first anniversary and the remainder ratably over eight quarters. According to the company, each RSU converts to one common share with no exercise price.

Why were the inducement awards for PSTV approved by the compensation committee?

The awards were approved to comply with Nasdaq Rule 5635(c)(4) for inducement grants to new employees. According to the company, the Compensation Committee approved the awards as material inducements for new hires.

What is the potential shareholder impact of the PSTV March 2026 inducement awards?

The awards potentially increase diluted shares by up to 600,000 if all awards vest and convert to shares. According to the company, the grants were made as standard inducement awards under the company's equity plan.